Mark S. Levine Sells 2,505 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock

Immunovant, Inc. (NASDAQ:IMVT) insider Mark S. Levine sold 2,505 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $29.69, for a total transaction of $74,373.45. Following the transaction, the insider now directly owns 337,409 shares in the company, valued at approximately $10,017,673.21. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Immunovant Price Performance

Shares of IMVT stock opened at $27.97 on Monday. The stock’s fifty day moving average price is $27.84 and its 200 day moving average price is $31.93. Immunovant, Inc. has a 1-year low of $18.82 and a 1-year high of $45.58. The company has a market cap of $4.09 billion, a price-to-earnings ratio of -14.72 and a beta of 0.67.

Immunovant (NASDAQ:IMVT) last issued its quarterly earnings results on Wednesday, May 29th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). During the same period last year, the firm posted ($0.46) earnings per share. As a group, equities research analysts anticipate that Immunovant, Inc. will post -2.11 earnings per share for the current year.

Institutional Trading of Immunovant

Several large investors have recently bought and sold shares of the stock. Assenagon Asset Management S.A. lifted its stake in shares of Immunovant by 198.0% during the second quarter. Assenagon Asset Management S.A. now owns 311,525 shares of the company’s stock worth $8,224,000 after buying an additional 207,003 shares during the period. SG Americas Securities LLC lifted its position in Immunovant by 638.7% during the 2nd quarter. SG Americas Securities LLC now owns 30,702 shares of the company’s stock worth $811,000 after acquiring an additional 26,546 shares during the period. DNB Asset Management AS grew its stake in Immunovant by 10.3% during the 2nd quarter. DNB Asset Management AS now owns 10,290 shares of the company’s stock valued at $271,000 after purchasing an additional 958 shares during the last quarter. Castleark Management LLC acquired a new position in shares of Immunovant in the first quarter valued at about $2,599,000. Finally, Bamco Inc. NY raised its stake in shares of Immunovant by 1.7% in the first quarter. Bamco Inc. NY now owns 60,000 shares of the company’s stock worth $1,939,000 after purchasing an additional 1,000 shares during the last quarter. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $51.00 price objective on shares of Immunovant in a research note on Thursday, May 30th. Oppenheimer dropped their target price on Immunovant from $50.00 to $46.00 and set an “outperform” rating on the stock in a research report on Monday, June 3rd. Truist Financial reiterated a “buy” rating and issued a $48.00 price target on shares of Immunovant in a report on Monday, March 25th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Immunovant in a research note on Tuesday, June 18th. Fifteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $49.73.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.